Post- Essential Thrombocythemia Myelofibrosis clinical trials at University of California Health
2 in progress, 1 open to eligible people
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
open to eligible people ages 18 years and up
A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that have not been previously treated with Janus kinase inhibitors (JAKi). Pelabresib is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
at UCLA UCSD
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
Sorry, not currently recruiting here
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
at UCLA
Our lead scientists for Post- Essential Thrombocythemia Myelofibrosis research studies include Gary Schiller, MD Catriona Jamieson.
Last updated: